Study to Assess the Effect of Meplazumab on COVID-19

NCT04586153 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Meplazumab for Injection
DRUG: Sterile normal saline (0.9%)

Sponsor

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd